2013 Apr 15 Annual Report 2012 - Phosphagenics

More documents

Recommendations

Info

Additional Shareholder Information continued BUY-BACK The Company has not undertaken any share buy-back plans during or since the year ended 31 December 2012 SUBSTANTIAL SHAREHOLDINGS The following Substantial Shareholdings (‘SSH’) have been declared to the Company : Holder of relevant interest Entitlement to No. securities Date of SSH Notice Form No. Orbis Global Equity Fund Ltd 133,609,911 22.03.2012 604 Harry Rosen 64,226,436 16.01.2012 604 Ross G Copeland 45,175,335 14.09.2011 603 Broking Commissions: Not applicable. UNQUOTED OPTIONS OPTIONS : EXPIRED 31 MARCH 2013 As at closed of buisness on 31 March 2013 the Company had received applications for the exercise of 250,000 options at an exercise price of $0.142 an option. 114 As such, a total of 4,750,000 March 31 2013 options automatically lapsed through non-exercise. Following clearance of funds the Company will be issuing 250,000 new ordinary fully paid shares arising from the the exercise of the 31 March 2013 options. VOTING RIGHTS : The 31 March 2013 Options carried no voting rights. OPTIONS : 22 MAY 2014 Twenty Largest Holdings : (expiring 22 May 2014 & exercisable at 17.0cents each.) Number Options Held % Issued Capital Ranking Mr K Poutakidis 1,000,000 100.00 1 The options are fully vested and may be exercised at any time before the stated expiry date. VOTING RIGHTS : Options carry no voting rights. Employee Share Option Plan (“The Plan”) As at the date of this report the Company has on issue under the terms & conditions of the PLAN an aggregate of 3.25 million ESOP options with various expiry dates and exercise prices. The options may be exercised at any time before the stated expiry date after they have become fully vested. As at the date of this report no ESOP options have been exercised. A summary of the options issued under the PLAN is: Granted 15,900,000 Less Lapsed -12,650,000 Number of options now on issue 3,250,000 Number fully vested options 3,250,000 Number non-vested options - 3,250,000 On a fully diluted basis the number of unexercised ESOP options (3,250,000) represents 0.31 per cent of all issued securities VOTING RIGHTS : ESOP Options carry no voting rights. PHOSPHAGENICS ANNUAL REPORT 2012
Additional Shareholder Information continued UNQUOTED RESTRICTED SECURITIES Conditional Rights At the 2011 Annual General Meeting shareholders approved the establishment of an employees Conditional Rights Plan. At the same meeting shareholders approved and authorised the Company to issue a total of 5,800,000 Rights to the directors noted in the various resolutions. In addition to the 5,800,00 shareholder authorised Rights the Company has issued, in total, 13,450,000 Rights to employees bringing the total number of Rights issued under the Plan to 19,250,000. Up to and including 1 April 2013 a total of 2,300,00 employee Rights have lapsed leaving a total of non-exercised Rights of 16,950,000 as at 1 April 2013. All Rights have been issued on the terms set out in the Explanatory Memorandum accompanying the Notice of Meeting for the 2011 Annual General Meeting. Upon the achievement of the stated milestones and having vested the Rights may be exercised on the basis of one new ordinary Phosphagenics Limited share for each Right so exercised. The Rights and any shares issued pursuant to the exercise of the Rights are subject to the restrictions as set out in the Conditional Rights Plan document as referred to the the 2011 Annual General Meeting documentation. As at the date of this information no Rights have vested. 115 ADDITIONAL SHAREHOLDER INFORMATION
Page 1 and 2:
20 12 Annual Report PHOSPHAGENICS P
Page 3 and 4:
highlights March... April... May...
Page 5 and 6:
03 Jonathan Addison Chairman & Inde
Page 7 and 8:
COLLABORATIONS Strategic Collaborat
Page 9 and 10:
The Phosphagenics Evolution THE STO
Page 11 and 12:
“ We also reached agreement with
Page 13 and 14:
Overview of our opioid development
Page 15 and 16:
13 is branded as Butrans or Norspan
Page 17 and 18:
Personal Care ASHLAND INC (FORMERLY
Page 19 and 20:
BEAUTY IS MORE THAN SKIN DEEP 17 EL
Page 21 and 22:
cellulite contour crème BioElixia
Page 23 and 24:
Intellectual Property Title Countri
Page 25 and 26:
2009 2008 2007 2006 6.8 7.8 22.2 23
Page 27 and 28:
DR ESRA OGRU (AGED 37 YEARS) BSC (H
Page 29 and 30:
Senior Management DR PAUL GAVIN Chi
Page 31 and 32:
Phosphagenics Limited ABN 32 056 48
Page 33 and 34:
Directors’ Report Your directors
Page 35 and 36:
Directors’ Report continued Looki
Page 37 and 38:
Directors’ Report continued Commi
Page 39 and 40:
Directors’ Report continued REMUN
Page 41 and 42:
Page 43 and 44:
Directors’ Report continued Share
Page 45 and 46:
Directors’ Report continued Share
Page 47 and 48:
Exercise Price Expiry Date Net othe
Page 49 and 50:
Exercise Price Expiry Date Net othe
Page 51 and 52:
Fair value per performance right at
Page 53 and 54:
Page 55 and 56:
Auditors Independence Declaration 5
Page 57 and 58:
Corporate Governance Statement cont
Page 59 and 60:
Page 61 and 62:
Page 63 and 64:
Page 65 and 66: Corporate Governance Statement cont
Page 67 and 68: Consolidated statement of fi nancia
Page 69 and 70: Consolidated statement of changes i
Page 71 and 72: Notes to the consolidated fi nancia
Page 73 and 74: Application date of standard Impact
Page 113 and 114: Independent Auditor’s Report 111
Page 115: Additional Shareholder Information
Page 119: corporate directory Phosphagenics L
show all

2013 Apr 15 Annual Report 2012 - Phosphagenics

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?